



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release

30 December, 2021

## Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital

Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær has been invited to J.P. Morgan 40<sup>th</sup> Annual Healthcare Conference which will take place 10-13 January 2022. Furthermore, Curasight will present a Deep Dive event in Brain cancer at HC Andersen Capital, 19 January 2022.

The presentation at HC Andersen Capital will be webcasted live 11:00 - 11:30 (CET), Wednesday 19 January 2022.

For more information – please [click here](#)

The presentation will be in English.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel theranostic platform with Positron Emissions Tomography (PET) imaging Radionuclide Therapy targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis, risk stratification and therapy in multiple cancer types.